Invested Advisors Buys New Shares in Gilead Sciences, Inc. $GILD

Invested Advisors purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,415 shares of the biopharmaceutical company’s stock, valued at approximately $601,000. Gilead Sciences makes up 0.8% of Invested Advisors’ holdings, making the stock its 28th largest holding.

A number of other hedge funds have also recently made changes to their positions in the business. Railway Pension Investments Ltd increased its position in shares of Gilead Sciences by 3.1% during the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after acquiring an additional 42,200 shares during the period. TriaGen Wealth Management LLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at approximately $1,274,000. Invesco Ltd. grew its stake in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Sivik Global Healthcare LLC increased its holdings in Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after purchasing an additional 10,000 shares during the period. Finally, One Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after acquiring an additional 2,364 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 3.0%

NASDAQ:GILD opened at $120.67 on Friday. The company has a market capitalization of $149.71 billion, a P/E ratio of 18.71, a PEG ratio of 0.66 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70. The firm has a fifty day simple moving average of $123.24 and a 200-day simple moving average of $117.41.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total value of $366,000.00. Following the sale, the insider directly owned 106,221 shares in the company, valued at $12,958,962. This represents a 2.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 136,257 shares of company stock valued at $16,855,192. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on GILD. HSBC lifted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Needham & Company LLC upped their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. TD Cowen lifted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Daiwa Capital Markets increased their price objective on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.20.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.